Table 2.
Recent RCT and PSM studies regarding outcomes of liver resection vs radiofrequency ablation for HCC
| Author | Year | Type | Treatments | Liver function factor | Tumor factor | Survival | RFS |
|---|---|---|---|---|---|---|---|
| Chen et al42 | 2006 | RCT |
LR (n = 90) vs RFA (n = 71) |
CP‐A ICG‐R15 <30% Plt >40 000/mm3 |
Single Size ≤5 cm |
NSD LR 3 y 73.4% RFA 3 y 71.4% |
NSD LR 3 y 69.0% RFA 3 y 64.1% |
| Huang et al43 | 2010 | RCT |
LR (n = 115) vs RFA (n = 115) |
CP‐A and B ICG‐R15 <20% Plt >50 000/mm3 |
Within Milan criteria |
LR > RFA LR 3 y 92.2% RFA 3 y 69.6% |
LR > RFA LR 3 y 60.9% RFA 3 y 46.1% |
| Feng et al44 | 2012 | RCT |
LR (n = 84) vs RFA (n = 84) |
CP‐A and B ICG‐R15 <30% Plt >50 000/mm3 |
Single/2 nodules Size ≤4 cm |
NSD LR 3 y 74.8% RFA 3 y 67.2% |
NSD LR 3 y 61.1% RFA 3 y 49.6% |
| Fang et al45 | 2014 | RCT |
LR (n = 60) vs RFA (n = 60) |
CP‐A and B Plt >50 000/mm3 |
Single/2/3 nodules Size ≤3 cm |
NSD LR 3 y 77.5% RFA 3 y 82.5% |
NSD LR 3 y 41.3% RFA 3 y 55.4% |
| Jiang et al46 | 2015 | PSM |
LR (n = 140) vs RFA (n = 140) |
BCLC stage A |
Single/2 nodules Size ≤3 cm |
NSD LR 3 y 74.8% RFA 3 y 72.9% |
LR > RFA LR 3 y 52.4% RFA 3 y 35.8% |
| Kim et al47 | 2016 | PSM |
LR (n = 152) vs RFA (n = 152) |
PS 0, CP‐A |
Single nodules Size ≤3 cm |
NSD | NSD |
| Liu et al39 | 2016 | PSM |
LR (n = 79) vs RFA (n = 79) |
BCLC stage 0 |
Single Size ≤ 2 cm |
NSD LR 3 y 97% RFA 3 y 88% |
LR > RFA LR 3 y 64% RFA 3 y 38% |
| Chong et al41 | 2017 | PSM |
LR (n = 121) vs RFA (n = 121) |
BCLC stage 0/A |
Single/2/3 nodules Size ≤3 cm |
LR > RFA LR 3 y 90% RFA 3 y 76% |
LR > RFA LR 3 y 63% RFA 3 y 30% |
BCLC, Barcelona Clinic Liver Cancer; CP, Child‐Pugh; HCC, hepatocellular carcinoma; ICG, indocyanine green retention test; LR, liver resection; NSD, no significant difference; Plt, platelets; PS, performance status; PSM, propensity‐score matched study; RCT, randomized controlled trial; RFA, radiofrequency ablation.